RADX to meet U.S. FDA on RAD 101 Phase 3 trial design
Radiopharm Theranostics (RADX) says it will meet with the U.S. FDA to align on pivotal Phase 3 trial design for RAD 101 in the diagnosis of brain metastases.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.